Reference : Strontium Ranelate: A New Treatment for Postmenopausal Osteoporosis with a Dual Mode of ...
Scientific journals : Article
Human health sciences : Rheumatology
http://hdl.handle.net/2268/25334
Strontium Ranelate: A New Treatment for Postmenopausal Osteoporosis with a Dual Mode of Action
English
Reginster, Jean-Yves mailto [Université de Liège - ULg > Département des sciences de la santé publique > Epidémiologie et santé publique >]
Sarlet, Nathalie [Centre Hospitalier Universitaire de Liège - CHU > > Médecine de l'appareil locomoteur >]
LEJEUNE, Eric mailto [Centre Hospitalier Universitaire de Liège - CHU > > Médecine de l'appareil locomoteur >]
Leonori, Lorenzo mailto [Centre Hospitalier Universitaire de Liège - CHU > > Médecine de l'appareil locomoteur >]
Mar-2005
Current Osteoporosis Reports
3
1
30-4
Yes (verified by ORBi)
International
1544-1873
[en] In vitro, strontium ranelate increases collagen and noncollagen protein synthesis by mature osteoblast-enriched cells. Its effects on bone formation were confirmed as the drug enhanced preosteoblastic cell replication. In the isolated osteoclast, preincubation of bone slices with strontium ranelate-induced dose-dependent inhibition of the bone-resorbing activity of treated rat osteoclast. Strontium ranelate dose-dependently inhibited preosteoclast differentiation. Its effect in postmenopausal women with established osteoporosis was assessed during an international, prospective, double-blind, randomized, placebo-controlled phase 3 program comparing strontium ranelate 2 g daily with placebo. The 3-year analysis of the phase 3 study, Spinal Osteoporosis Therapeutic Intervention, evaluating the effect of strontium ranelate 2 g/day on vertebral fracture rates, revealed a significant 41% reduction in the relative risk of patients experiencing new vertebral fracture with strontium ranelate over 3 years. A second phase 3 study showed a significant reduction in the relative risk of experiencing a nonvertebral fracture in the group treated with strontium ranelate over 3 years. These results show that strontium ranelate is a new, effective, and safe treatment for vertebral and hip osteoporosis, with a unique mode of action, increasing bone formation and decreasing bone resorption leading to a rebalance of bone turnover in favor of bone formation.
http://hdl.handle.net/2268/25334

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
Strontium Ranelate A New Treatment.pdfPublisher postprint48.17 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.